Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Safety System Will Be Improved By Medicare Rx, HHS Secretary Tells PhRMA

This article was originally published in The Pink Sheet Daily

Executive Summary

The Part D benefit will allow HHS to gather useful postmarketing data to help improve the regulation of drug safety, Leavitt says. The HHS Secretary dowplays the need for legislative changes at FDA.

You may also be interested in...



FDA Advisory Committees To Help Decide Medicare Rx Data Research Agenda

Claims data collected on prescriptions filled through the Medicare drug benefit will be used by outside groups to produce evidence on drugs' safety and effectiveness. FDA advisory committees, AHRQ and IoM could help determine study priorities, CMS says.

FDA Advisory Committees To Help Decide Medicare Rx Data Research Agenda

Claims data collected on prescriptions filled through the Medicare drug benefit will be used by outside groups to produce evidence on drugs' safety and effectiveness. FDA advisory committees, AHRQ and IoM could help determine study priorities, CMS says.

FDA Drug Safety Oversight Board Will Include VA, Other Agencies

The panel is the primary feature of FDA's proposal to reform drug safety review within the agency; other features include the creation of a drug safety website. The panel and website are intended to increase drug safety "oversight" and "openness" at FDA.

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel